Date published: 2026-5-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

STI1 Inhibitors

STI1 inhibitors constitute a significant class of chemical compounds that have garnered considerable interest within the realm of cellular biology. These inhibitors specifically target the STI1 protein, also known as Hsp90, which functions as a crucial molecular chaperone within the cell. The chaperone role of STI1 involves facilitating the proper folding and stabilization of diverse client proteins, many of which are essential for pivotal cellular functions. By interacting with STI1, these inhibitors interfere with its chaperone activity, thereby potentially disrupting the normal folding processes of its client proteins.

The chemical structure of STI1 inhibitors displays a notable diversity, allowing for a wide range of interactions with the intricate architecture of the STI1 protein. Researchers have diligently employed various techniques, including computational modeling, structural analysis, and high-throughput screening, to identify and refine potential STI1 inhibitors. These inhibitors are designed to bind to specific regions of the STI1 protein's three-dimensional structure, leading to structural alterations that compromise its functional capacity.

This, in turn, could impact the stability and proper conformation of client proteins that rely on STI1 assistance for appropriate folding. The significance of STI1 inhibitors lies in their potential to unravel complex cellular mechanisms that hinge upon STI1-mediated protein folding. By selectively inhibiting STI1's chaperone activity, these compounds offer a unique avenue for dissecting intricate cellular pathways and exploring novel biochemical interactions. Although the broader implications of STI1 inhibitors remain a subject of ongoing research and exploration, their capacity to perturb protein folding pathways through targeted STI1 modulation holds promise for advancing our comprehension of cellular processes at a fundamental level. Consequently, the pursuit of STI1 inhibitors not only contributes to expanding our knowledge of molecular biology but also paves the way for the development of innovative chemical tools that can unravel the intricacies of cellular functions.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits tyrosine kinases, particularly BCR-ABL, by binding to the ATP-binding site, blocking the phosphorylation of target proteins, and interfering with cellular signaling pathways involved in cancer growth.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Targets epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the ATP-binding site, preventing receptor autophosphorylation, and downstream signaling cascades, ultimately inhibiting proliferation and survival in cancer cells.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Inhibits multiple kinases, including RAF kinases and receptor tyrosine kinases, disrupting angiogenesis and tumor cell growth by interfering with MAPK and PI3K/AKT signaling pathways.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Targets multiple receptor tyrosine kinases, such as VEGFR and PDGFR, leading to inhibition of angiogenesis and tumor cell proliferation by disrupting signaling pathways involved in cell growth and survival.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Binds to multiple tyrosine kinases, including BCR-ABL and SRC family kinases, interfering with their activity and disrupting downstream signaling cascades implicated in cancer progression.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Inhibits EGFR tyrosine kinase activity by competing with ATP for the ATP-binding site, leading to suppressed phosphorylation of downstream targets and hindrance of cancer cell growth and proliferation.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Targets both EGFR and HER2/neu receptors, disrupting their tyrosine kinase activity and downstream signaling pathways, thereby inhibiting the growth and survival of cancer cells overexpressing these receptors.